MedTrace Logo

Motion Sickness Severity and Sensorimotor Performance

NCT07619469 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2026-06-26

No results posted yet for this study

Summary

Background: Motion sickness (MS) is a common syndrome characterized by autonomic and behavioral symptoms, such as nausea and dizziness, resulting from exposure to motion stimuli. Its pathophysiology is closely linked to sensory conflict and postural instability theories. While previous studies suggest that postural control, proprioception, and reaction times are affected in individuals susceptible to MS, there is a lack of comprehensive, comparative research evaluating all these parameters concurrently within the same cohort using standardized methods. Objective: This study aims to systematically measure balance, proprioceptive sensitivity, coordination, and reaction time parameters, and quantitatively analyze their relationship with motion sickness severity. Methodology: In this prospective, cross-sectional study, at least 41 participants aged 18-40 with motion sickness will be recruited. Participants will undergo motion sickness susceptibility and severity grading using the Motion Sickness Susceptibility Questionnaire Short Form (MSSQ-SF) and the Graybiel Scale. Objective assessments will include static and dynamic balance testing (ProKin®), knee joint position sense (Clinometer app), manual dexterity and dynamic balance coordination (Nine-Hole Peg Test, Tandem Walk, Romberg Test), and upper/lower extremity reaction time measurements (BlazePod system).

Conditions

Interventions

OTHER

Standardized Sensorimotor Assessment and Motion Sickness Provocation Protocol

Participants will undergo a standardized battery of sensorimotor assessments, including static/dynamic balance tracking, knee joint position sense testing, manual dexterity/coordination tasks, and upper/lower extremity reaction time measurements, alongside a controlled motion sickness provocation session using a randomized chair-rotation protocol."

Sponsors & Collaborators

  • Istinye University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2026-08-02
Completion
2026-08-05

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07619469 on ClinicalTrials.gov